Polaryx Therapeutics, Inc. Total Operating Expenses decreased by 61.2% to $1.96M in Q1 2026 compared to the prior quarter. This increase may warrant attention — for this metric, lower values are generally preferred.
Rising expenses without a corresponding rise in revenue can indicate operational bloat or aggressive expansion efforts.
The sum of all costs required to run the business that are not directly tied to production, including R&D and SG&A. It r...
Investors compare this to revenue to assess the 'operating leverage' of a business model.
total_operating_expenses| Q1 '25 | Q1 '26 | |
|---|---|---|
| Value | $5.05M | $1.96M |
| QoQ Change | — | -61.2% |
| YoY Change | — | -61.2% |